Disinfectant composition comprising phage of
The present invention provides a disinfectant composition including a phage of Acinetobacter baumannii and a carrier. The present invention also provides a method for disinfecting a medical institute or a medical research institute, including the steps of applying an effective amount of a phage of Acinetobacter baumannii to the medical institute or the medical research institute for reducing amount of Acinetobacter baumannii in the medical institute or the medical research institute.
1. A disinfectant composition, comprising:
a lytic phage of Acinetobacter baumannii ; and
a carrier,
wherein the phage is compatible with the carrier so as to keep bioactivity of the phage; and
wherein the phage of Acinetobacter baumannii possesses an icosahedral head and a short tail.
2. The disinfectant composition of claim 1 , wherein the phage of Acinetobacter baumannii comprises at least one pure strain of Acinetobacter baumannii phages.
3. The disinfectant composition of claim 1 , wherein the phage of Acinetobacter baumannii specifically infects Acinetobacter baumannii.
4. The disinfectant composition of claim 1 , wherein the Acinetobacter baumannii is drug-resistant Acinetobacter baumannii.
5. The disinfectant composition of claim 4 , wherein the drug-resistant Acinetobacter baumannii has resistance to at least one antibiotics selected form the group consisting of gentamicin, amikacin, piperacillin/tazobactam, ticarcillin/clavulanate, ceftazidime, cefepime, cefpirome, aztreonam, imipenem, meropenem, ciprofloxacin, and levofloxacin.
6. The disinfectant composition of claim 1 , wherein the phage of Acinetobacter baumannii is a Podoviridae phage having a double stranded DNA genome.
7. The disinfectant composition of claim 1 , further comprising a phage of Acinetobacter baumannii possessing an icosahedral head and a contractile tail.
8. The disinfectant composition of claim 7 , wherein the phage of Acinetobacter baumannii possessing an icosahedral head and a contractile tail is a Myoviridae phage having a double stranded DNA genome.
9. The disinfectant composition of claim 1 , wherein the phage of Acinetobacter baumannii has bioactivity at pH 4 to pH 12.
10. The disinfectant composition of claim 1 , being a solution, suspension, powder, spray or ointment.
11. The disinfectant composition of claim 1 , wherein the carrier is one selected from the group consisting of water, oil, a surfactant, peptone and a combination thereof.
12. The disinfectant composition of claim 11 , wherein the surfactant is at least one selected from the group consisting of an anionic surfactant, a cationic surfactant, an amphoteric surfactant and a non-ionic surfactant.
13. The disinfectant composition of claim 11 , wherein the surfactant is a non-ionic surfactant.
14. The disinfectant composition of claim 1 , further comprising another phage of bacterium causing nosocomial infections.
15. The disinfectant composition of claim 14 , wherein the bacterium causing nosocomial infections is at least one selected from the group consisting of Acinetobacter, Staphylococcu, Enterococci, Enterobacteriaceae , Non-fermentative gram-negative bacilli, Legionella, Clostridium, Mycobacterium and Pseudomonas.
16. The disinfectant composition of claim 1 , wherein an initial concentration of the phage of Acinetobacter baumannii is 1×10 7 PFU/ml to 1×10 9 PFU/ml.
17. A method for disinfecting a medical institute or a medical research institute, comprising the step of applying the composition of claim 1 in the medical institute or the medical research institute for reducing amount of bacteria in the medical institute or the medical research institute.
18. The method of claim 17 , wherein the step of applying is performed via directly spraying, indirectly spraying, immersing or greasing.